Females who are pregnant or lactating, fertile males, or females of child-bearing potential who are not willing to comply with an effective double method of birth control are NOT eligible for participation
Females of child-bearing potential and sexually-active males must consent to follow acceptable birth control methods to avoid contraception while on treatment
Sexually active females of childbearing potential and males with partners of child bearing potential must agree to use birth control
Females of child bearing potential and males with female partners must and use of contraceptive methods with a failure rate of less than or equal to (</=)% per year is required during treatment and for  months post treatment. Males should not expose pregnant partners to sperm and refrain from donating sperm for  months post treatment
Males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods
Females and males must agree to contraceptive methods and avoid conceiving throughout the study, and for up to  weeks following the last dose of CC-. If participating in Part B, females of child bearing potential should continue to use effective contraceptive methods for  months following treatment with rituximab
For males and females of child-producing potential, use of effective contraceptive methods during the study to include  methods of contraception, one being a condom
In females with childbearing potential, or men with partners of child bearing potential, willingness to use adequate contraception for a minimum duration of  days in females and  days in males, after last dose of nivolumab
Males and females not willing to use effective contraception.
Females of reproductive potential that are pregnant or lactating, and males or females not willing to use a highly effective form of contraception from Screening through the end of the study.
Females of childbearing potential and males who are not surgically sterile and with partners of childbearing potential must agree to use effective contraception during study treatment for  months for females and  months for males after the last dose of nivolumab
Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control during study treatment
Participants who are pregnant or lactating; males or females of reproductive potential must agree to use effective contraception for the duration of study participation
Must be males or non-pregnant females who agree to comply with applicable contraceptive requirements of the protocol.
Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for  months after completion of therapy
Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for  months after completion of therapy
Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for  months after completion of therapy
Females of childbearing potential and males must agree to use an acceptable form of contraception per institutional practices
Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control during study treatment
Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control during study treatment
Females of child bearing potential and sexually active males must agree to use adequate birth control during study treatment
WOCBP and males with partners of child-bearing potential must agree to use adequate birth control throughout their participation and for  months following the last study treatment
Males of child bearing potential must agree to practice effective barrier contraception during the entire study treatment period and through  months) after the last dose of study drug, (includes males surgically sterilized  i.e. status post vasectomy).
Negative serum beta-HCG in females, and use of effective contraception in males and females of child-bearing potential, is required
Pregnant or breast-feeding; for males and females of child-producing potential, inability to use effective contraceptive methods during the study
All sexually active subjects (males and females of child-bearing potential) agree to use  effective methods of contraception for the duration of the study
Patients, both females and males, of reproductive potential must agree to use adequate contraception during and for six months after the last infusion of tisotumab vedotin.
Willingness to use effective contraception (both males and females of child-bearing potential) throughout the study and for at least  months after study treatment.
Males and females of reproductive age and childbearing potential must use effective contraception for the duration of their participation
Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and continuing ( weeks for females,  weeks for males) after the last dose of nivolumab
Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for  months after completion of therapy
Females and males of reproductive potential must use effective contraception during and after treatment for  months
Patients, both females and males, of childbearing/reproductive potential must agree to use adequate contraception while included in the trial and for six months after the last infusion of HuMax-AXL-ADC
Males and females must agree, in the consent form, to use effective birth control methods during the course of vaccination
Females of childbearing potential and males not using adequate birth control.
Females of child-bearing potential and males who use adequate birth control through  days post dose.
Females of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for  months following the last dose of study medication.
Subjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study
Fertile males or females of childbearing potential agree to use adequate contraception prior to study entry
Males with female partners of child bearing potential must agree to use protocol defined methods of contraception (see below) and agree to refrain from donating sperm for the duration of the study
Patients, both females and males, of reproductive potential must agree to use adequate contraception during and for six months after the last infusion of HuMax-TF-ADC.
Females of child-bearing potential must have a negative serum pregnancy test within  days prior to start of study treatment and must use an adequate method of contraception during the study. All sexually active males must also use an adequate method of contraception during the study.
Sexually active females of child bearing potential and males must agree to use effective contraception for the duration of the transplant period
Females of child-bearing potential and sexually-active males must consent to follow acceptable birth control methods to avoid contraception while on treatment
Both females and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for  days following the last dose of study drug
For males and females of child-bearing potential, willingness to use adequate birth control through  days after the last dose of epacadostat or atezolizumab.
Females of childbearing potential and males must agree to use effective contraception as defined by protocol during the treatment period and for at least  months after the last dose of study drug
Patients, both females and males, of reproductive potential must agree to use adequate contraception during and for six months after the last infusion of HuMax-TF-ADC.
Pregnant or lactating females are excluded. Women of childbearing age, and their sexual partners, must use an effective contraception program. Males who are having sexual relations with women capable of child bearing must use the barrier birth control while on the study and for - months after the last dose of the study drug.
. Fertile males and females must agree to the use of an adequate form of contraception, e.g., condoms for males.
Pregnant or lactating females are excluded. Women of childbearing age, and their sexual partners, must use an effective contraception program. Males who are having sexual relations with women capable of child bearing must use birth control while on the study and for -months after the last dose of the study drug.
Females and males must be willing to use an approved form of birth control while on this study and for  weeks after completion.
Females or males whose partners are women of childbearing potential must agree to use a reliable method of birth control prior to drug initiation and for the duration of their study participation
Males and females must agree to use effective contraception starting prior to the first day of treatment and continuing for  days after the last dose of GC
For males and females of child-producing potential, use of effective contraceptive methods during the study and for at least  months after the last dose of romidepsin
Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for  months after completion of therapy
Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control during study treatment
Females (of child bearing potential) and males (of child bearing potential) must be abstinent or agree to use birth control during the study
